[Federal Register Volume 81, Number 191 (Monday, October 3, 2016)]
[Notices]
[Pages 68020-68021]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23854]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of Correction for Announcement of Requirements and 
Registration for ``Antimicrobial Resistance Rapid, Point-of-Need 
Diagnostic Test'' Challenge

    The National Institutes of Health (NIH) is correcting a notice 
previously published in the Federal Register on September 8, 2016 (81 
FR 62150), titled ``Announcement of Requirements and Registration for 
`Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test' 
Challenge.'' The notice announced the Antimicrobial Resistance Rapid, 
Point-of-Need challenge competition that may result in the awarding of 
$20 million dollars for the successful development of new, innovative, 
accurate, and cost-effective in vitro diagnostic tests that would 
rapidly inform clinical treatment decisions and be of significant 
clinical and public health utility to combat the development and spread 
of antibiotic resistant bacteria and improve antibiotic stewardship.
    The NIH is correcting and clarifying several components of the 
Challenge competition including:
    (1) The letter of intent must be submitted by December 23, 2016, 
for all ``Solvers'' planning to submit for the Step 1 (Theoretical) 
stage of the competition. The September 8, 2016 announcement 
incorrectly stated that the letter of intent prior to Step 1 was

[[Page 68021]]

required but a specific due date was not stated.
    (2) Any Appendix submitted for Step 1 of the Challenge competition 
must be limited to 5 pages or less in length. If a longer Appendix is 
submitted, only the first 5 pages will be considered by the Technical 
Evaluation Panel and the Judging Panel. The September 8, 2016, 
announcement incorrectly stated that there was no page length for the 
Appendix material.
    (3) Submissions for Step 1 of the Challenge competition received 
after the deadline of January 9, 2017, at 11:59 p.m. ET will be 
disqualified and not evaluated by the Technical Evaluation Panel or 
Judging Panel.
    (4) Solvers may submit corrections or additional materials in 
support of their Step 1 submissions so long as the NIH receives the 
materials by the deadline of January 9, 2017, at 11:59 p.m. ET. 
Corrections or additional materials for Step 1 will not be accepted or 
evaluated by the Technical Evaluation Panel or Judging Panel if they 
are received after January 9, 2017 at 11:59 p.m. ET.
    (5) The NIH will perform an initial review of all submissions to 
ensure they are complete and within the scope of the Challenge 
competition. Submissions that are incomplete will be administratively 
disqualified and will not be evaluated by the Technical Evaluation 
Panel or the Judging Panel.
    (6) The NIH and Assistant Secretary for Preparedness and Response/
Biomedical Advanced Research and Development Authority may determine 
that based on the number of submissions received for Step 1 that less 
competitive submissions will not be discussed by the Technical 
Evaluation Panel during the Panel's meeting.
    (7) The ``Solver'' needs to address the NIH Human Subjects 
Protections and Inclusion of Women, Children, and Minorities policies 
in their submissions for Step 1 of this competition.
    (8) Members of the Technical Evaluation Panel are not eligible to 
participate in or contribute to any proposal for Step 2 and Step 3 of 
the Challenge competition.
    (9) Any Solver is eligible for Step 2 of this Challenge 
competition. For example, if a Step 1 ``Solver'' is not identified as a 
semifinalist, he/she may still submit for Step 2 of this competition 
and those who did not submit a Step 1 proposal may still submit a 
proposal for Step 2.
    (10) All submissions for Step 1, 2, and 3 must be in English.
    For further information about the Antimicrobial Resistance 
Diagnostic Challenge competition, please contact Robert W. Eisinger, 
Ph.D., NIH, 301-496-2229 or by email [email protected].

    Dated: September 27, 2016.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2016-23854 Filed 9-30-16; 8:45 am]
 BILLING CODE 4140-01-P